Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Imaging Glioblastoma Posttreatment: Progression, Pseudoprogression, Pseudoresponse, Radiation Necrosis.

Strauss SB, Meng A, Ebani EJ, Chiang GC.

Radiol Clin North Am. 2019 Nov;57(6):1199-1216. doi: 10.1016/j.rcl.2019.07.003. Epub 2019 Aug 16. Review.

PMID:
31582045
2.

Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Delgado-López PD, Riñones-Mena E, Corrales-García EM.

Clin Transl Oncol. 2018 Aug;20(8):939-953. doi: 10.1007/s12094-017-1816-x. Epub 2017 Dec 7. Review.

PMID:
29218626
3.

Tl-201 SPECT and F-18 FDG PET for assessment of glioma recurrence versus radiation necrosis.

Siepmann DB, Siegel A, Lewis PJ.

Clin Nucl Med. 2005 Mar;30(3):199-200. No abstract available.

PMID:
15722830
4.

Differentiation of Recurrent Glioblastoma from Delayed Radiation Necrosis by Using Voxel-based Multiparametric Analysis of MR Imaging Data.

Yoon RG, Kim HS, Koh MJ, Shim WH, Jung SC, Kim SJ, Kim JH.

Radiology. 2017 Oct;285(1):206-213. doi: 10.1148/radiol.2017161588. Epub 2017 May 23.

PMID:
28535120
5.

[Pseudoprogression or pseudoresponse: a challenge for the diagnostic imaging in Glioblastoma multiforme].

Payer F.

Wien Med Wochenschr. 2011 Jan;161(1-2):13-9. doi: 10.1007/s10354-010-0860-8. Review. German.

PMID:
21312094
6.

Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.

Liu ZC, Yan LF, Hu YC, Sun YZ, Tian Q, Nan HY, Yu Y, Sun Q, Wang W, Cui GB.

BMC Med Imaging. 2017 Feb 1;17(1):10. doi: 10.1186/s12880-017-0183-y.

7.

Radiation Necrosis, Pseudoprogression, Pseudoresponse, and Tumor Recurrence: Imaging Challenges for the Evaluation of Treated Gliomas.

Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S, Argyropoulou MI.

Contrast Media Mol Imaging. 2018 Dec 2;2018:6828396. doi: 10.1155/2018/6828396. eCollection 2018. Review.

8.

Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study.

Ismail M, Hill V, Statsevych V, Huang R, Prasanna P, Correa R, Singh G, Bera K, Beig N, Thawani R, Madabhushi A, Aahluwalia M, Tiwari P.

AJNR Am J Neuroradiol. 2018 Dec;39(12):2187-2193. doi: 10.3174/ajnr.A5858. Epub 2018 Nov 1.

9.

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape.

Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ.

J Neurooncol. 2017 Sep;134(3):495-504. doi: 10.1007/s11060-017-2375-2. Epub 2017 Apr 5. Review.

10.

Role of FDG-PET/MRI, FDG-PET/CT, and Dynamic Susceptibility Contrast Perfusion MRI in Differentiating Radiation Necrosis from Tumor Recurrence in Glioblastomas.

Hojjati M, Badve C, Garg V, Tatsuoka C, Rogers L, Sloan A, Faulhaber P, Ros PR, Wolansky LJ.

J Neuroimaging. 2018 Jan;28(1):118-125. doi: 10.1111/jon.12460. Epub 2017 Jul 18.

11.

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials.

Ellingson BM, Wen PY, Cloughesy TF.

Neurotherapeutics. 2017 Apr;14(2):307-320. doi: 10.1007/s13311-016-0507-6. Review.

12.

Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy.

Wald LL, Nelson SJ, Day MR, Noworolski SE, Henry RG, Huhn SL, Chang S, Prados MD, Sneed PK, Larson DA, Wara WM, McDermott M, Dillon WP, Gutin PH, Vigneron DB.

J Neurosurg. 1997 Oct;87(4):525-34.

PMID:
9322843
13.

(18)F-fluoromethylcholine (FCho), (18)F-fluoroethyltyrosine (FET), and (18)F-fluorodeoxyglucose (FDG) for the discrimination between high-grade glioma and radiation necrosis in rats: a PET study.

Bolcaen J, Descamps B, Deblaere K, Boterberg T, De Vos Pharm F, Kalala JP, Van den Broecke C, Decrock E, Leybaert L, Vanhove C, Goethals I.

Nucl Med Biol. 2015 Jan;42(1):38-45. doi: 10.1016/j.nucmedbio.2014.07.006. Epub 2014 Aug 15.

PMID:
25218024
14.

Preradiotherapy MR Imaging: A Prospective Pilot Study of the Usefulness of Performing an MR Examination Shortly before Radiation Therapy in Patients with Glioblastoma.

Majós C, Cos M, Castañer S, Pons A, Gil M, Fernández-Coello A, Macià M, Bruna J, Aguilera C.

AJNR Am J Neuroradiol. 2016 Dec;37(12):2224-2230. Epub 2016 Sep 8.

15.

Incidence of intracranial radiation necrosis following postoperative radiation therapy for sinonasal malignancies.

Ahmad S, Le CH, Chiu AG, Chang EH.

Laryngoscope. 2016 Nov;126(11):2445-2450. doi: 10.1002/lary.26106. Epub 2016 Jun 14.

PMID:
27296477
16.

Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.

Yun TJ, Park CK, Kim TM, Lee SH, Kim JH, Sohn CH, Park SH, Kim IH, Choi SH.

Radiology. 2015 Mar;274(3):830-40. doi: 10.1148/radiol.14132632. Epub 2014 Oct 21.

PMID:
25333475
17.

Post-treatment imaging changes in primary brain tumors.

O'Brien BJ, Colen RR.

Curr Oncol Rep. 2014;16(8):397. doi: 10.1007/s11912-014-0397-x. Review.

PMID:
24997979
18.

Serial FLT PET imaging to discriminate between true progression and pseudoprogression in patients with newly diagnosed glioblastoma: a long-term follow-up study.

Brahm CG, den Hollander MW, Enting RH, de Groot JC, Solouki AM, den Dunnen WFA, Heesters MAAM, Wagemakers M, Verheul HMW, de Vries EGE, Pruim J, Walenkamp AME.

Eur J Nucl Med Mol Imaging. 2018 Dec;45(13):2404-2412. doi: 10.1007/s00259-018-4090-4. Epub 2018 Jul 21.

19.

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ.

Lancet Oncol. 2008 May;9(5):453-61. doi: 10.1016/S1470-2045(08)70125-6. Review.

PMID:
18452856
20.

Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Shiroishi MS, Boxerman JL, Pope WB.

Neuro Oncol. 2016 Apr;18(4):467-78. doi: 10.1093/neuonc/nov179. Epub 2015 Sep 12. Review.

Supplemental Content

Support Center